drugset / Trial / NCT01024517

GLPG0259 Solid Formulation Bioavailability and Food Effect

NCT01024517

Phase 1 Completed 12 enrolled Lakefront Biotherapeutics NV
RandomizedCrossoverOpen-label

Summary

The purpose of the study is to compare the pharmacokinetics of GLPG0259 as a solid dosage formulation (with and without food)and an oral solution, and to assess its safety and tolerability.

Timeline

Start
2009-11
Primary completion
2009-12
Completion
2010-02

Drugs

EvaluationDrugModalityDoseRoute
Subject GLPG0259 Small molecule 50 mg Oral

Indications

No indication recorded.